Literature DB >> 36062233

The Latest on Lung Ablation.

Peyton Cramer1, Bradley B Pua1.   

Abstract

Lung cancer is the second most common cancer in both men and women. Despite smoking cessation efforts and advances in lung cancer detection and treatment, long-term survival remains low. For early-stage primary lung carcinoma, surgical resection offers the best chance of long-term survival; however, only about one-third of patients are surgical candidates. For nonsurgical candidates, minimally invasive percutaneous thermal ablation therapies have become recognized as safe and effective treatment alternatives, including radiofrequency ablation, microwave ablation, and cryoablation. Lung ablation is also an acceptable treatment for limited oligometastatic and oligorecurrent diseases. This article discusses the technologies and techniques available for tumor ablation of thoracic malignancies, as well as new treatments on the horizon. Thieme. All rights reserved.

Entities:  

Keywords:  cryoablation; interventional radiology; lung cancer; microwave ablation; radiofrequency ablation

Year:  2022        PMID: 36062233      PMCID: PMC9433157          DOI: 10.1055/s-0042-1753526

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.780


  74 in total

Review 1.  Evaluation and treatment of high-risk patients with early-stage lung cancer.

Authors:  Hiren J Mehta; Christopher Ross; Gerard A Silvestri; Roy H Decker
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

2.  Lung radiofrequency ablation for the treatment of unresectable recurrent non-small-cell lung cancer after surgical intervention.

Authors:  Hiroshi Kodama; Koichiro Yamakado; Haruyuki Takaki; Masataka Kashima; Junji Uraki; Atsuhiro Nakatsuka; Motoshi Takao; Osamu Taguchi; Tomomi Yamada; Kan Takeda
Journal:  Cardiovasc Intervent Radiol       Date:  2011-07-06       Impact factor: 2.740

3.  Local Control and Survival after Image-Guided Percutaneous Ablation of Adrenal Metastases.

Authors:  Nathan E Frenk; Dania Daye; Kemal Tuncali; Ronald S Arellano; Paul B Shyn; Stuart G Silverman; Florian J Fintelmann; Raul N Uppot
Journal:  J Vasc Interv Radiol       Date:  2017-09-18       Impact factor: 3.464

Review 4.  The Role of Percutaneous Image-Guided Thermal Ablation for the Treatment of Pulmonary Malignancies.

Authors:  Samdeep K Mouli; Ieva Kurilova; Constantinos T Sofocleous; Robert J Lewandowski
Journal:  AJR Am J Roentgenol       Date:  2017-06-28       Impact factor: 3.959

5.  Percutaneous radiofrequency ablation of pulmonary metastases from colorectal carcinoma: prognostic determinants for survival.

Authors:  Tristan D Yan; Julie King; Adrian Sjarif; Derek Glenn; Karin Steinke; David L Morris
Journal:  Ann Surg Oncol       Date:  2006-09-29       Impact factor: 5.344

6.  Percutaneous radiofrequency ablation of pulmonary malignancies: combined treatment with brachytherapy.

Authors:  Sapna K Jain; Damian E Dupuy; Gene A Cardarelli; Zhen Zheng; Thomas A DiPetrillo
Journal:  AJR Am J Roentgenol       Date:  2003-09       Impact factor: 3.959

7.  Percutaneous radiofrequency ablation for pulmonary metastases from colorectal cancer: midterm results in 27 patients.

Authors:  Takao Hiraki; Hideo Gobara; Tatsuhiko Iishi; Yoshifumi Sano; Toshihiro Iguchi; Hiroyasu Fujiwara; Nobuhisa Tajiri; Jun Sakurai; Hiroshi Date; Hidefumi Mimura; Susumu Kanazawa
Journal:  J Vasc Interv Radiol       Date:  2007-10       Impact factor: 3.464

8.  Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases.

Authors:  T de Baère; A Aupérin; F Deschamps; P Chevallier; Y Gaubert; V Boige; M Fonck; B Escudier; J Palussiére
Journal:  Ann Oncol       Date:  2015-02-16       Impact factor: 32.976

9.  Thermal Ablation in the Management of Adrenal Metastasis Originating from Non-small Cell Lung Cancer: A 5-year Single-center Experience.

Authors:  Evanthia I Botsa; Ioanna L Thanou; Aspasia T Papatheodoropoulou; Loukas I Thanos
Journal:  Chin Med J (Engl)       Date:  2017-09-05       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.